Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer
BackgroundImmuno-oncology (IO) therapies targeting the PD-1/PD-L1 axis, such as immune checkpoint inhibitor (ICI) antibodies, have emerged as promising treatments for early-stage breast cancer (ESBC). Despite immunotherapy's clinical significance, the number of benefiting patients remains small...
Main Authors: | Daniel Cook, Matthew Biancalana, Nicole Liadis, Dorys Lopez Ramos, Yuhan Zhang, Snehal Patel, Joseph R. Peterson, John R. Pfeiffer, John A. Cole, Anuja K. Antony |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Artificial Intelligence |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/frai.2023.1153083/full |
Similar Items
-
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
by: Patrick Wayne Cobb, et al.
Published: (2020-09-01) -
Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
by: Yuanshan Yao, et al.
Published: (2022-04-01) -
Biophysical models in radiation oncology /
by: 418919 Cohen, Lionel
Published: (1983) -
Epistemic dwelling: precision immuno-oncology by design
by: Luca Chiapperino, et al.
Published: (2021-01-01) -
Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
by: Alessandra Cesano, et al.
Published: (2018-02-01)